Spyre Therapeutics (SYRE) CFO Scott Burrows Buys $218K of Stock
CFO Scott Burrows acquired 15,000 shares of Spyre Therapeutics, Inc. on June 25, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Scott Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. ($SYRE), bought 15,000 shares at an average price of $14.50, worth about $217,500, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SYRE is down 2.3% after 1 week, up 12.8% after 1 month and down 9.9% to date (from the $88.67 close on Jun 25, 2026).
SYRE
Spyre Therapeutics, Inc.
Key Points
- Scott Burrows, CFO of Spyre Therapeutics, purchased 15,000 shares at $14.50 each on June 25, 2026, totaling $217,500.
- Spyre Therapeutics, Inc., a biotech firm, trades on NasdaqGS under SYRE, with a market cap of $7.7 billion and a 52-week high of $102.06.
- Analysts maintain a strong buy consensus for SYRE, with a mean price target of $100.47 among 15 analysts.
Get $SYRE trade alerts by text
We text you when insiders, Congress or big funds trade $SYRE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Spyre Therapeutics, Inc. alert may contain errors. Disclosures
Scott Burrows, the Chief Financial Officer of Spyre Therapeutics, Inc. (NASDAQ: SYRE), purchased 15,000 shares of the company on June 25, 2026. The shares were bought at an average price of $14.50 each, amounting to a total transaction value of $217,500. This move was not part of a pre-arranged trading plan.
Insider Buying and Selling at Spyre Therapeutics, Inc.
On the same day, Scott Burrows sold 15,000 shares at an average price of $87.13 each. Additionally, Fairmount Funds Management LLC executed several transactions on June 23, involving both purchases and sales of Spyre Therapeutics shares.
Other Institutional Activity in Spyre Therapeutics
FMR LLC increased its holdings in Spyre Therapeutics by 142,205 shares, bringing its total to 11,781,024 shares valued at approximately $594.2 million. BlackRock, Inc. slightly trimmed its position by 880 shares, maintaining 5,521,221 shares worth about $278.5 million. Meanwhile, Perceptive Advisors LLC significantly boosted its stake by 714,000 shares, ending with 3,783,225 shares valued at roughly $190.8 million.
Spyre Therapeutics, Inc. Stock Down 2.6%
As of Saturday, shares of Spyre Therapeutics traded near $88.67. The company, with a market capitalization of approximately $7.7 billion, operates in the biotechnology sector. Despite not being profitable, Spyre has a forward P/E ratio of -28.34 and a high beta of 3.06, indicating volatility. The stock's 52-week range spans from $14.00 to $102.06, with a 50-day moving average of $75.57.
Analysts Set New Price Targets
On June 23, 2026, Deutsche Bank maintained its buy rating on Spyre Therapeutics, setting a price target of $135. BTIG also kept its buy rating with a $112 target on June 16. Overall, the consensus among 15 analysts is a strong buy, with an average target price of $100.47.
About Spyre Therapeutics
Spyre Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing treatments for inflammatory bowel disease and rheumatic diseases. Notable projects include SPY001, a monoclonal antibody for ulcerative colitis and Crohn's disease, and other clinical-stage programs targeting various immune system pathways. The company, led by CEO Dr. Cameron Turtle, was founded in 2013 and employs 112 people.
Bottom Line
Scott Burrows' purchase of Spyre Therapeutics shares highlights insider confidence in the company's prospects. Investors often watch insider transactions for potential insights into a company's future. While 13F filings and insider trades offer valuable information, they reflect past actions and may not indicate current holdings or future moves.
Related Filing Alerts
Source: Scott Burrows's Form 4 filing on $SYRE (Jun 25, 2026). Find the original filing: SYRE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts